Product Images Xarelto

This text contains data on the pharmacokinetics of rivaroxaban in individuals with end-stage renal disease and renal impairment, differentiated by severity, as well as in individuals of different ages and body weights. The data includes peak concentration (Cmax) and area under the curve (AUC) measurements, along with fold change and 90% confidence intervals. The study also delves into the effects of hepatic impairment on the pharmacokinetics of rivaroxaban.*

This appears to be a table or list of drugs and their corresponding PK Fold Changes and 90% CI (Confidence Interval) when interacting with other drugs. The interactions are categorized based on whether they are P-gp (P-glycoprotein) or CYP3A (Cytochrome P450 3A) inhibitors or inducers. The table also includes some miscellaneous drugs and their corresponding Cmax (maximum concentration) and Auc (area under the curve) values. The last column shows the change relative to Rivaroxaban alone.*

This table represents the results of a study involving a drug called XARELTO compared to placebo. The table shows the cumulative incidence rate (%) at different days from randomization, with the number of subjects at risk for both the drug and the placebo group.*

This appears to be a table or chart showing the cumulative incidence rate (%) for two different treatment groups, identified as XARELTO and Placebo. The Hazard Ratio for these groups is also listed as 0.85-0.76, indicating a risk reduction for the XARELTO group. The rest of the text may be indicating time periods, but without context it is difficult to accurately describe.*

This is a short excerpt from a document that provides instructions for using a bottle adaptor. It advises the reader not to remove the bottle adaptor. Not much additional information can be discerned from this fragment of text.*

This text appears to be an instruction to check the expiration date of a product. The specific phrase "Discard after" suggests that the product has a limited lifespan and should not be used beyond a certain point for safety or efficacy reasons.*

This is a table showing the volume of different solutions. The first column indicates the total volume of the solution, while the second column shows the amounts of two different components added together to make up the total volume. The third column expands on this idea and shows the components of each solution in more detail.*

The text contains only two words: "bottle" and "adaptor". It doesn't provide enough context for a specific description.*

This is the description: This is a medication called Xarelto, with GTIN number 00350458577600 and NDC number 50458-577-60. Each tablet contains 2.5mg of rivaroxaban. It is a prescription medication and 60 tablets are included in the package. A medication guide should be provided to each patient. The text also includes some unreadable characters and is not properly formatted.*

This is a package label for a medication called Xarelto. The medication is in tablet form and contains 15mg of rivaroxaban. The label includes information on dosage, storage instructions, lot number, and expiration date. It also provides the National Drug Code (NDC) and GTIN identification numbers for the medication. Patients should be given a Medication Guide along with the tablets.*

This is a description of the medication Xarelto (rivaroxaban) which comes in a bottle of 90 tablets. Each tablet contains 20 mg of rivaroxaban. A medication guide should be dispensed to each patient along with the tablets. The text also includes an NDC number which could be used for tracking purposes.*

Xarelto is a medication used for the treatment of deep vein thrombosis and pulmonary embolism. The starter pack provides a 30-day supply, with the first 21 days consisting of a 15mg tablet taken twice a day and the remaining days consisting of a 20mg tablet taken once a day. It is recommended to see a doctor before starting the treatment and to take the medication exactly as prescribed without changing the dose or stopping unless instructed by a doctor. The package contains additional instructions on how to open it and store it properly. This medication should be kept out of reach of children.*

This is a description of Xarelto, a medication with the active ingredient rivaroxaban for oral suspension. The bottle contains 155mg of rivaroxaban, which is made in Germany and manufactured for Janssen Pharmaceuticals. The dosage and administration instructions are provided in the prescribing information, and the suspension must be used within 60 days once reconstituted. The pharmacist must reconstitute the medication before dispensing and counsel the caregiver on its proper use. The medication should be stored at room temperature and kept out of reach of children. The rest of the text explains how to reconstitute the suspension using a plastic bottle adapter and dosing syringes.*